Pidacmeran
**Semantic type:** Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance
**Definition:** A formulation consisting of lipid nanoparticle (LNP) encapsulating a specific form of messenger RNA encoding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of pidacmeran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.
**Synonyms:** - BNT 162c2 - BNT-162c2 - BNT1162c2 SARS-CoV-2 Vaccine - BNT162c2 - BNT162c2 COVID-19 Vaccine - PIDACMERAN
/api/v1/systems/nci_thesaurus/nodes/C173056Hierarchy Explorer
Cross-system equivalences0
No cross-system equivalences mapped for this node.